The strengths of our study include the following: (a) it is the first research study to investigate the associations between HLA class I and II alleles and the age at cancer diagnosis using a genetically confirmed LS cohort; (b) the utilization of high-throughput HLA genotyping using NGS in this regard; (c) the homogenous nature of the study cohort as patients harbor the same LS-PV in the hMLH1 gene and are originating from a population of a common ethnicity; and (d) new evidence suggesting that HLA allele variations may influence the age at cancer diagnosis in LSVH. Here, MLH1 is linked to cancer.